Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Transplant medications

M O'Donnell1, K L Parmenter

  • 1Cardiac Surgical Service, Massachusetts General Hospital, Boston, USA.

Critical Care Nursing Clinics of North America
|September 1, 1996
PubMed
Summary

This article details common medications for lung transplant recipients to prevent rejection and infection. It covers antibacterial, antiviral, and antifungal drugs, along with immunosuppressive regimens for lung transplant patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anatomical and functional characteristics of symptomatic post-TB lung disease.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2025
Same author

Stakeholder attitudes to a potential national registry for interstitial lung disease.

Irish medical journal·2025
Same author

Safety and feasibility of a virtual exercise programme for pulmonary fibrosis.

Irish medical journal·2025
Same author

Experiences of key populations in multidrug-resistant TB and HIV.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2025
Same author

Canadian Surgery Forum: Abstracts of presentations to the Annual Meetings of the Canadian Association of Bariatric Physicians and Surgeons, Canadian Association of General Surgeons, Canadian Association of Thoracic Surgeons, Canadian Hepato-Pancreato-Biliary Association, Canadian Society of Surgical Oncology, Canadian Society of Colon and Rectal Surgeons, Vancouver, BC, Sept. 17-21, 2013.

Canadian journal of surgery. Journal canadien de chirurgie·2025
Same author

Pandemic impacts and experiences after disaster in Australia: qualitative study of compound impacts following the Black Summer bushfires.

BJPsych open·2024

Area of Science:

  • Immunology
  • Pharmacology
  • Transplantation Medicine

Background:

  • Lung transplantation is a life-saving procedure for end-stage lung disease.
  • Graft rejection and opportunistic infections are significant challenges post-transplantation.
  • Effective immunosuppression and antimicrobial prophylaxis are crucial for long-term graft survival and patient health.

Purpose of the Study:

  • To provide a comprehensive overview of commonly used medications in lung transplant recipients.
  • To categorize and discuss immunosuppressive drug regimens for rejection prevention and treatment.
  • To identify essential antibacterial, antiviral, and antifungal agents for managing infections in this population.

Main Methods:

  • Review of current literature and clinical guidelines on immunosuppressive and antimicrobial therapies in lung transplantation.
  • Categorization of immunosuppressive drugs based on their role in induction, maintenance, and treatment of rejection.
  • Identification of commonly prescribed antibacterial, antiviral, and antifungal medications.
  • Compilation of medication characteristics, including indications, mechanisms of action, adverse reactions, and nursing implications, into tables.

Main Results:

  • Common three- and four-drug immunosuppressive regimens for lung transplant rejection are detailed.
  • Key antibacterial, antiviral, and antifungal agents used in lung transplant patients are identified.
  • Tables provide a quick reference for medication indications, mechanisms, adverse effects, and nursing considerations.

Conclusions:

  • Optimal medication selection and management are vital for preventing rejection and infection in lung transplant recipients.
  • Understanding the characteristics of these drugs is essential for healthcare providers to ensure patient safety and optimize outcomes.
  • This review serves as a practical resource for clinicians managing lung transplant patients.

Related Experiment Videos